Resverlogix Corp. (TSE:RVX – Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as C$0.06 and last traded at C$0.06, with a volume of 5250 shares. The stock had previously closed at C$0.06.
Resverlogix Stock Performance
The business has a 50 day moving average price of C$0.06 and a two-hundred day moving average price of C$0.07. The stock has a market cap of C$14.97 million, a PE ratio of -1.10 and a beta of 0.78.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Featured Stories
- Five stocks we like better than Resverlogix
- ETF Screener: Uses and Step-by-Step Guide
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Trading Halts Explained
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Insider Buying Explained: What Investors Need to Know
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.